Genome Interpretation, Nanoparticles, Gene Therapy, 2024 IPOs; Nautilus Biotechnology
About this episode
Episode 7 (February 2, 2024): Simplify Genomics launches genome interpretation platform, COUR’s nanoparticles for autoimmunity, gene replacement therapy for heart condition, CG Oncology and ArriVent IPOs; an interview with Nautilus Biotechnology co-founders, Sujal Patel and Parag Mallick.
Listed below are key references to the GEN stories, media and other items discussed in this episode of Touching Base:
Human Longevity Spin-Out Aims to Tap into Variant Interpretation Market
By Uduak Thomas, GEN, January 31st, 2024
Light My Fire: COUR Raises $105M Series A to Advance Tolerogenic Nanoparticles for Autoimmunity
By Jonathan Grinstein, GEN Edge, January 30th, 2024
Gene Replacement Therapy Halts Fatal Arrhythmogenic Condition in Mice
GEN, January 30th, 2024
StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M
By Alex Philippidis, GEN Edge, January 28th, 2024
Hosted on Acast. See acast.com/privacy for more information.
Get every episode summarized
Each time Touching Base publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Touching Base
BMS’s New Facility, Recursion–Genentech Partnership, Long-COVID and Persistent C...
Touching Base
Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntingt...
Touching Base
Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics
Touching Base
Merck and Insilico Make Deals, Claude Science’s Debut, Vaccines for Neglected Di...
Touching Base